Skip to contentS
Syndax Pharmaceuticals Inc
S
SNDXSyndax Pharmaceuticals Inc Q1 2023 · 10-Q
Revenue—
Net Income-$41.13M-$41.13MN/M vs Q1 2022 EPS Diluted-$0.59-$0.59N/M vs Q1 2022 Operating Income-$46,015,000N/M Operating Cash Flow-$39,228,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Syndax Pharmaceuticals Inc · CIK 1395937 · Engraved from SEC EDGAR
ended Mar 31, 2023 · filed May 8, 2023 · 38 d after period end